Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial

Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2023-06, Vol.136 (12), p.1491-1493
Main Authors: Xia, Yi, Wang, Li, Ding, Kaiyang, Wu, Jiazhu, Yin, Hua, Hu, Maogui, Shen, Haorui, Liang, Jinhua, Chen, Ruize, Li, Yue, Zhu, Huayuan, Li, Jianyong, Xu, Wei
Format: Article
Language:English
Subjects:
Aminopyridines - therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Cell cycle
Clinical trials
Correspondence
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Kinases
Lymphoma
Lymphoma, Non-Hodgkin - drug therapy
Medical prognosis
Patients
Remission (Medicine)
Stem cell transplantation
T cell receptors
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83
cites cdi_FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83
container_end_page 1493
container_issue 12
container_start_page 1491
container_title Chinese medical journal
container_volume 136
creator Xia, Yi
Wang, Li
Ding, Kaiyang
Wu, Jiazhu
Yin, Hua
Hu, Maogui
Shen, Haorui
Liang, Jinhua
Chen, Ruize
Li, Yue
Zhu, Huayuan
Li, Jianyong
Xu, Wei
description Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). [...]63 patients were included in the per-protocol set (PPS) [Supplementary Figure 1, http://links.lww.com/CM9/B617]. [...]chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.
doi_str_mv 10.1097/CM9.0000000000002636
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2703eed36fee49a8a36172088c0be6e9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2703eed36fee49a8a36172088c0be6e9</doaj_id><sourcerecordid>2799829360</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83</originalsourceid><addsrcrecordid>eNpdkkFv1DAQhSMEokvhHyAUiQuXFMeOHZsLKlGhKxVxgbM160w23nXiYCet-u_xsqW09cXWzPOnN0-TZW9LclYSVX9svqsz8uBQwcSzbEV5RQsuqvJ5tiJMiEIopU6yVzHukobzWrzMTlidWqosV9nS9LaFwbZYfLk4b_LJLTGHZfbOb316xhmH3KBz-RxgjJODcYbZ-jG3Y97bbV8EG_f56Mfi0rfbfaq622Hq_QCfcsinHiLm63VunB2tgQPGgnudvejARXxzd59mv75e_Gwui6sf39bN-VVheCV5wTpWY0eIogQ4Nx3dANSVqWqoWqwMaSnhtAMlCAUETkRFaGfqumKcCWkkO83WR27rYaenYAcIt9qD1X8LPmw1hNkah5qmSBBbJjrESoEEJsqaEikN2aBAlVifj6xp2QzYGhxTIu4R9HFntL3e-mtdElpLIXkifLgjBP97wTjrwcZDtjBiyjpZUEpSxQRJ0vdPpDu_hDFlpamkyVdZy8N41VFlgo8xYHfvpiT6sCQ6LYl-uiTp27uHk9x_-rcV_7k33s0Y4t4tNxh0j-Dm_sBLJhkpKKGMCEpIkUolZ38AEfjG7w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2827201788</pqid></control><display><type>article</type><title>Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Xia, Yi ; Wang, Li ; Ding, Kaiyang ; Wu, Jiazhu ; Yin, Hua ; Hu, Maogui ; Shen, Haorui ; Liang, Jinhua ; Chen, Ruize ; Li, Yue ; Zhu, Huayuan ; Li, Jianyong ; Xu, Wei</creator><creatorcontrib>Xia, Yi ; Wang, Li ; Ding, Kaiyang ; Wu, Jiazhu ; Yin, Hua ; Hu, Maogui ; Shen, Haorui ; Liang, Jinhua ; Chen, Ruize ; Li, Yue ; Zhu, Huayuan ; Li, Jianyong ; Xu, Wei</creatorcontrib><description>Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). [...]63 patients were included in the per-protocol set (PPS) [Supplementary Figure 1, http://links.lww.com/CM9/B617]. [...]chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.1097/CM9.0000000000002636</identifier><identifier>PMID: 37036911</identifier><language>eng</language><publisher>China: Lippincott Williams &amp; Wilkins</publisher><subject>Aminopyridines - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Cell cycle ; Clinical trials ; Correspondence ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Kinases ; Lymphoma ; Lymphoma, Non-Hodgkin - drug therapy ; Medical prognosis ; Patients ; Remission (Medicine) ; Stem cell transplantation ; T cell receptors ; Transplantation, Autologous</subject><ispartof>Chinese medical journal, 2023-06, Vol.136 (12), p.1491-1493</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83</citedby><cites>FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278685/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2827201788?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37036911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xia, Yi</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Ding, Kaiyang</creatorcontrib><creatorcontrib>Wu, Jiazhu</creatorcontrib><creatorcontrib>Yin, Hua</creatorcontrib><creatorcontrib>Hu, Maogui</creatorcontrib><creatorcontrib>Shen, Haorui</creatorcontrib><creatorcontrib>Liang, Jinhua</creatorcontrib><creatorcontrib>Chen, Ruize</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><creatorcontrib>Zhu, Huayuan</creatorcontrib><creatorcontrib>Li, Jianyong</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><title>Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial</title><title>Chinese medical journal</title><addtitle>Chin Med J (Engl)</addtitle><description>Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). [...]63 patients were included in the per-protocol set (PPS) [Supplementary Figure 1, http://links.lww.com/CM9/B617]. [...]chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.</description><subject>Aminopyridines - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Cell cycle</subject><subject>Clinical trials</subject><subject>Correspondence</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Stem cell transplantation</subject><subject>T cell receptors</subject><subject>Transplantation, Autologous</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkkFv1DAQhSMEokvhHyAUiQuXFMeOHZsLKlGhKxVxgbM160w23nXiYCet-u_xsqW09cXWzPOnN0-TZW9LclYSVX9svqsz8uBQwcSzbEV5RQsuqvJ5tiJMiEIopU6yVzHukobzWrzMTlidWqosV9nS9LaFwbZYfLk4b_LJLTGHZfbOb316xhmH3KBz-RxgjJODcYbZ-jG3Y97bbV8EG_f56Mfi0rfbfaq622Hq_QCfcsinHiLm63VunB2tgQPGgnudvejARXxzd59mv75e_Gwui6sf39bN-VVheCV5wTpWY0eIogQ4Nx3dANSVqWqoWqwMaSnhtAMlCAUETkRFaGfqumKcCWkkO83WR27rYaenYAcIt9qD1X8LPmw1hNkah5qmSBBbJjrESoEEJsqaEikN2aBAlVifj6xp2QzYGhxTIu4R9HFntL3e-mtdElpLIXkifLgjBP97wTjrwcZDtjBiyjpZUEpSxQRJ0vdPpDu_hDFlpamkyVdZy8N41VFlgo8xYHfvpiT6sCQ6LYl-uiTp27uHk9x_-rcV_7k33s0Y4t4tNxh0j-Dm_sBLJhkpKKGMCEpIkUolZ38AEfjG7w</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>Xia, Yi</creator><creator>Wang, Li</creator><creator>Ding, Kaiyang</creator><creator>Wu, Jiazhu</creator><creator>Yin, Hua</creator><creator>Hu, Maogui</creator><creator>Shen, Haorui</creator><creator>Liang, Jinhua</creator><creator>Chen, Ruize</creator><creator>Li, Yue</creator><creator>Zhu, Huayuan</creator><creator>Li, Jianyong</creator><creator>Xu, Wei</creator><general>Lippincott Williams &amp; Wilkins</general><general>Lippincott Williams &amp; Wilkins Ovid Technologies</general><general>Wolters Kluwer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230620</creationdate><title>Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial</title><author>Xia, Yi ; Wang, Li ; Ding, Kaiyang ; Wu, Jiazhu ; Yin, Hua ; Hu, Maogui ; Shen, Haorui ; Liang, Jinhua ; Chen, Ruize ; Li, Yue ; Zhu, Huayuan ; Li, Jianyong ; Xu, Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aminopyridines - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Cell cycle</topic><topic>Clinical trials</topic><topic>Correspondence</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Stem cell transplantation</topic><topic>T cell receptors</topic><topic>Transplantation, Autologous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xia, Yi</creatorcontrib><creatorcontrib>Wang, Li</creatorcontrib><creatorcontrib>Ding, Kaiyang</creatorcontrib><creatorcontrib>Wu, Jiazhu</creatorcontrib><creatorcontrib>Yin, Hua</creatorcontrib><creatorcontrib>Hu, Maogui</creatorcontrib><creatorcontrib>Shen, Haorui</creatorcontrib><creatorcontrib>Liang, Jinhua</creatorcontrib><creatorcontrib>Chen, Ruize</creatorcontrib><creatorcontrib>Li, Yue</creatorcontrib><creatorcontrib>Zhu, Huayuan</creatorcontrib><creatorcontrib>Li, Jianyong</creatorcontrib><creatorcontrib>Xu, Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xia, Yi</au><au>Wang, Li</au><au>Ding, Kaiyang</au><au>Wu, Jiazhu</au><au>Yin, Hua</au><au>Hu, Maogui</au><au>Shen, Haorui</au><au>Liang, Jinhua</au><au>Chen, Ruize</au><au>Li, Yue</au><au>Zhu, Huayuan</au><au>Li, Jianyong</au><au>Xu, Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chin Med J (Engl)</addtitle><date>2023-06-20</date><risdate>2023</risdate><volume>136</volume><issue>12</issue><spage>1491</spage><epage>1493</epage><pages>1491-1493</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><abstract>Chidamide, a novel subtype-selective histone deacetylase inhibitor (HDACi), can directly inhibit tumor cell cycle progression, induce tumor cell apoptosis, and restore the sensitivity of drug-resistant tumor cells to drugs by loosening chromatin and exposing deoxyribonucleic acid (DNA). The protocol of this study was approved by the Institutional Review Board of Jiangsu Province Hospital and Anhui Provincial Cancer Hospital (No. 2017-SR-271). [...]63 patients were included in the per-protocol set (PPS) [Supplementary Figure 1, http://links.lww.com/CM9/B617]. [...]chidamide with anti-programmed cell death protein 1 achieved an objective response rate of 58.3% and a CR rate of 44.4% in treating advanced and relapsed/refractory ENKTL.</abstract><cop>China</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>37036911</pmid><doi>10.1097/CM9.0000000000002636</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2023-06, Vol.136 (12), p.1491-1493
issn 0366-6999
2542-5641
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2703eed36fee49a8a36172088c0be6e9
source HEAL-Link subscriptions: Lippincott Williams & Wilkins; Publicly Available Content Database; PubMed Central
subjects Aminopyridines - therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Cell cycle
Clinical trials
Correspondence
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Kinases
Lymphoma
Lymphoma, Non-Hodgkin - drug therapy
Medical prognosis
Patients
Remission (Medicine)
Stem cell transplantation
T cell receptors
Transplantation, Autologous
title Chidamide-BEAC plus autologous stem cell transplantation in high-risk non-Hodgkin lymphoma: a phase II clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A35%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chidamide-BEAC%20plus%20autologous%20stem%20cell%20transplantation%20in%20high-risk%20non-Hodgkin%20lymphoma:%20a%20phase%20II%20clinical%20trial&rft.jtitle=Chinese%20medical%20journal&rft.au=Xia,%20Yi&rft.date=2023-06-20&rft.volume=136&rft.issue=12&rft.spage=1491&rft.epage=1493&rft.pages=1491-1493&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.1097/CM9.0000000000002636&rft_dat=%3Cproquest_doaj_%3E2799829360%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5485-3f37ef00920a55cf2baa74c47a4de4c0d2052fa9602aea506402fc77435368c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2827201788&rft_id=info:pmid/37036911&rfr_iscdi=true